https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-announce-positive-top-line-results
- Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in Asia Pacific
top linepfizerannouncepositiveresults
https://www.clinicaltrialsarena.com/news/biohaven-rimegepant-phase-iii-data/
Biohaven Pharmaceutical has reported that a single dose of rimegepant has led to pain freedom in a Phase III trial involving migraine patients.
positive resultphase iiirimegepantshowsmigraine